What are the indications, dosing regimens, and contraindications for colchicine in adults?

Colchicine: Indications, Dosing, and Contraindications

Colchicine is FDA-approved for treating acute gout flares, preventing gout flares, and managing familial Mediterranean fever (FMF) in adults and children ≥4 years old. 1

Primary Indications

1. Acute Gout Flares (Treatment)

For acute gout attacks, administer 1.2 mg at the first sign of flare, followed by 0.6 mg one hour later (total 1.8 mg over 1 hour). 1, 2 This low-dose regimen is equally effective as higher doses but causes significantly fewer gastrointestinal side effects 2.

• Start within 12 hours of symptom onset for maximum efficacy 3
• If already on prophylactic colchicine, choose alternative therapy (NSAID or corticosteroid) 4
• Do not repeat treatment for at least 3 days 1

2. Gout Flare Prophylaxis

Use 0.6 mg once or twice daily (maximum 1.2 mg/day) when initiating urate-lowering therapy. 1 Continue prophylaxis for at least 6 months after starting urate-lowering agents like allopurinol or febuxostat 4, 3. This prevents the paradoxical increase in flares that occurs when mobilizing urate from tissue deposits 1.

3. Familial Mediterranean Fever

Adults require 1.2-2.4 mg daily, titrated in 0.3 mg increments based on disease control and tolerability. 1 Pediatric dosing is age-based:

• Ages 4-6 years: 0.3-1.8 mg daily
• Ages 6-12 years: 0.9-1.8 mg daily
• Ages >12 years: 1.2-2.4 mg daily 1

The goal is complete suppression of inflammatory attacks and normalization of serum amyloid A (SAA) to prevent AA amyloidosis 5.

4. Emerging Cardiovascular Indication

Low-dose colchicine (0.5 mg daily) received FDA approval in 2023 for reducing cardiovascular events in patients with established atherosclerotic disease 6. It reduces major adverse cardiovascular events by 31% in stable coronary disease and 23% post-myocardial infarction 6, though recent trials show inconsistent results in acute settings 7, 8.

Absolute Contraindications

Never use colchicine in patients with severe renal or hepatic impairment who are taking strong CYP3A4 inhibitors (clarithromycin, ketoconazole) or P-glycoprotein inhibitors (cyclosporine). 2, 1 This combination can be fatal due to massive drug accumulation 9, 10.

Additional contraindications:

• Systemic fungal infections (when considering corticosteroids as alternative)
• Concurrent use of strong CYP3A4/P-gp inhibitors without dose adjustment 3, 1

Critical Dose Adjustments

Renal Impairment

• Mild (eGFR 60-89): No adjustment needed 11
• Moderate (eGFR 30-59): Reduce to 0.48-0.5 mg daily for prophylaxis 11; for acute flares, use 1.2 mg × 1 dose only 1
• Severe (eGFR 15-29): Reduce to 0.3 mg daily for prophylaxis 11; for acute flares, use 0.6 mg × 1 dose 1
• Avoid in severe renal impairment during acute flares 3

Drug Interactions Requiring Dose Reduction

With strong CYP3A4 inhibitors (atazanavir, clarithromycin, ritonavir, ketoconazole, itraconazole):

• Prophylaxis: 0.3 mg once daily or 0.3 mg every other day 1
• Acute flare: 0.6 mg × 1 dose, followed by 0.3 mg 1 hour later; wait 3 days before repeating 1
• FMF: Maximum 0.6 mg daily 1

With moderate CYP3A4 inhibitors (diltiazem, verapamil, erythromycin, fluconazole):

• Prophylaxis: 0.3 mg twice daily or 0.6 mg once daily 1
• Acute flare: 1.2 mg × 1 dose only 1
• FMF: Maximum 1.2 mg daily 1

With P-gp inhibitors (cyclosporine, ranolazine): Same reductions as strong CYP3A4 inhibitors 1

Safety Monitoring

Common Adverse Effects

• Gastrointestinal toxicity (diarrhea, nausea, vomiting, cramping) is most common, occurring in 76% more patients than placebo 2, 8
• Reduce dose if intolerable; symptoms often improve with dose reduction 5

Serious Toxicity Warning

Colchicine overdose can be fatal. 9, 5 Toxicity progresses through three stages:

1. 0-24 hours: Severe gastrointestinal symptoms, dehydration, shock
2. 24-72 hours: Multiorgan failure, bone marrow suppression, cardiac arrhythmias, renal failure
3. Recovery phase: Rebound leukocytosis, alopecia 9

No antidote exists; management is purely supportive. 9, 10 Maximum safe doses are 3 mg/day in adults and 2 mg/day in children 9.

Monitoring Requirements

• Monitor complete blood count and liver enzymes regularly 5
• Check creatine kinase in patients with renal impairment or on statins (risk of neuromyopathy) 3, 5
• Assess adherence at each visit; non-adherence is common 5
• In FMF, monitor SAA or CRP to ensure inflammatory control 5

Clinical Pitfalls to Avoid

1. Do not use high-dose regimens for acute gout (the old 0.6 mg every 2 hours protocol causes severe diarrhea without added benefit) 2, 12
2. Do not combine colchicine with macrolide antibiotics (clarithromycin, erythromycin) without dose reduction—fatal toxicity reported 1
3. Do not ignore drug interactions with statins—combined use increases myopathy risk, especially with renal impairment 3, 5
4. Do not continue prophylactic dosing during acute flare treatment—wait 12 hours after acute dosing before resuming prophylaxis 1
5. Do not use IV colchicine—severe and fatal toxicity risk 12